...
首页> 外文期刊>The Journal of Nuclear Medicine >Organ and Fetal Absorbed Dose Estimates from 99mTc-Sulfur Colloid Lymphoscintigraphy and Sentinel Node Localization in Breast Cancer Patients
【24h】

Organ and Fetal Absorbed Dose Estimates from 99mTc-Sulfur Colloid Lymphoscintigraphy and Sentinel Node Localization in Breast Cancer Patients

机译:乳腺癌患者99mTc-硫胶体淋巴显像和前哨淋巴结定位的器官和胎儿吸收剂量估计

获取原文
           

摘要

id="p-1">The purpose of this retrospective study was to determine whether lymphoscintigraphy (LSG) for sentinel lymph node (SNL) mapping in a woman with a breast mass presents an unacceptable risk to her fetus. We assessed radiation-absorbed dose to various organs from 99mTc-sulfur colloid (TSC) LSG using standard internal absorbed dose assessment methodologies for both reference phantoms as well as for phantom models using the specific patient population characteristics such as total body and injected organ mass. The study also projected the radiation-absorbed dose to the fetus from LSG for SLN mapping. >Methods: Data from 1,021 nonpregnant women with early-stage breast cancer who underwent SLN mapping and biopsy procedures were analyzed. Patients had a single-site intradermal injection of unfiltered TSC in 0.05 mL normal saline: 3.7 MBq (0.1 mCi) on the morning of surgery (1-d protocol) or 18.5 MBq (0.5 mCi) on the afternoon before surgery (2-d protocol). A standard internal dose calculation methodology was used to calculate absorbed doses to various organs and to a modeled fetus at 3-, 6-, and 9-mo gestation from the injection site as well as from systemic activity. >Results: The highest estimated absorbed doses were observed for the reference 9-mo-pregnant model under the 2-d protocol. Absorbed doses of 14.9, 0.214, 0.062, 0.151, 0.004, 0.163, 0.075, and 0.014 mGy were received by the injected breast, heart, liver, lung, ovaries, thymus, total body, and fetus, respectively. Effective doses from the 2-d protocol were estimated to be 0.460, 0.186, and 0.245 mSv for the reference population, the total Memorial Sloan-Kettering Cancer Center (MSKCC) study patient population, and childbearing-age MSKCC patient population (i.e., 45 y old), respectively. >Conclusion: SLN procedures lead to a negligible dose to the fetus of 0.014 mGy or less. This is much less than the National Council on Radiation Protection and Measurements limit to a pregnant woman. Calculations using actual patient population characteristics resulted in lower organ dose estimates than more conservative reference models.
机译:id =“ p-1”>这项回顾性研究的目的是确定在乳腺肿块妇女中进行前哨淋巴结(SNL)映射的淋巴显像(LSG)是否会对胎儿造成不可接受的风险。我们使用标准内部吸收剂量评估方法,针对参考体模以及体模模型,使用特定的患者群体特征,例如,评估了 99m Tc-硫胶体(TSC)LSG对各个器官的辐射吸收剂量。作为整体和注入的器官质量。该研究还预测了从LSG对胎儿的辐射吸收剂量以用于SLN定位。 >方法:分析了1,021名接受SLN定位和活检程序检查的未怀孕早期乳腺癌妇女的数据。患者于手术当天上午(1-d方案)进行单部位皮内注射未过滤TSC的0.05 mL生理盐水:3.7 MBq(0.1 mCi)或手术前下午(2-d)进行18.5 MBq(0.5 mCi)协议)。使用标准的内部剂量计算方法来计算从注射部位到妊娠3个月,6个月和9个月时各个器官和模型胎儿的吸收剂量以及全身活动。 >结果:在2-d方案下,参考9个月妊娠模型观察到最高的估计吸收剂量。注射的乳房,心脏,肝脏,肺,卵巢,胸腺,全身和胎儿分别接受了14.9、0.214、0.062、0.151、0.004、0.163、0.075和0.014 mGy的吸收剂量。对于参考人群,纪念斯隆-凯特琳纪念中心(MSKCC)研究的患者人群和育龄MSKCC的患者人群,二维方案的有效剂量估计分别为0.460、0.186和0.245 mSv。 45岁)。 >结论:SLN程序对胎儿的剂量可忽略不计0.014 mGy或更少。这远低于全国辐射防护与测量委员会对孕妇的限制。使用实际患者人群特征进行的计算得出的器官剂量估算值要比更保守的参考模型低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号